Avantis Emerging Markets Equity ETF (ARCA: AVEM)

Últimas noticias sobre Avantis Emerging Markets Equity ETF (ARCA:AVEM)

Technology

Financial Services

Consumer Cyclical

Basic Materials

Industrials

Communication Services

Other

Energy

Consumer Defensive

Healthcare

Utilities

Real Estate

The fund invests primarily in a diverse group of companies related to emerging markets across market sectors, industry groups and countries. The fund may invest in companies of all market capitalizations. The fund seeks securities of companies that it expects to have higher returns by placing an enhanced emphasis on securities of companies with smaller market capitalizations and securities of companies with higher profitability and value characteristics. The portfolio managers define profitability mainly as adjusted cash from operations to book value ratio (though other ratios may be considered). The portfolio managers may also consider other factors when selecting a security, including industry classification, the past performance of the security relative to other securities, its liquidity, its float, and tax, governance or cost considerations, among others. When portfolio managers identify securities with the desired capitalization, profitability, value, and past performance characteristics, they seek to include and emphasize these securities in the broadly diversified portfolio.

Taiwan Semiconductor Manufacturing Co. Ltd. Sponsored ADR

Tencent Holdings Ltd

Samsung Electronics Co. Ltd. GDR

Alibaba

PDD Holdings Inc

Reliance Industries Ltd - GDR

Infosys Ltd

Avantis Emerging Markets Equity ETF

Government

News

Regulations

Tech

Media

AAPL

AVEM

Capital Group Global Growth Equity ETF Capital Group Global Growth Equity ETF

CGGO

NVDA

El gobierno de Taiwán estudia medidas para apoyar a Taiwan Semiconductor (TSM) frente a posibles aranceles de Trump.

Taiwán considera apoyos para TSMC ante amenazas arancelarias de Trump

Citizens Capital Markets analyst Matthew Condon reiterates Viant Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSP#NASDAQ">DSP</a>) with a Market Outperform and maintains $24 price target.

Price Target

Reiteration

Analyst Ratings

Citizens Capital Markets Reiterates Market Outperform on Viant Technology, Maintains $24 Price Target

Goldman Sachs analyst Carly Davenport maintains Edison Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EIX#NYSE">EIX</a>) with a Neutral and lowers the price target from $88 to $68.

Goldman Sachs Maintains Neutral on Edison Intl, Lowers Price Target to $68

Scotiabank analyst John Zamparo maintains Alimentation Couche-Tard (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ATD#TSX">ATD</a>) with a Sector Outperform and lowers the price target from C$91 to C$85.

TSX:ATD

Scotiabank Maintains Sector Outperform on Alimentation Couche-Tard, Lowers Price Target to C$85

WIIM

KKR shares are trading lower after the company announced $1.5 billion mandatory convertible preferred stock offering.

Guidance

Target CEO Says Expect To Invest $4B To $5B In Stores And Technology This Year; Target CEO Says Expect To Drive More Than $15B Revenue Growth Over The Next Five Years

Citizens Capital Markets analyst Jonathan Wolleben reiterates DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) with a Market Outperform and maintains $10 price target.

DBVT

Citizens Capital Markets Reiterates Market Outperform on DBV Technologies, Maintains $10 Price Target

&nbsp;<a href="https://www.globenewswire.com/Tracker?data=OVD19W71GIhFcu4212msH6-Y5-UXamivOVPsTWHp9U6Y1ysaHfPjPco0VENdSObzwLOlrsj-pFntIC98RZcO7KQGV-bJqjYI03KwVHu8HLU=">Freight Technologies, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRGT#NASDAQ">FRGT</a>)("Fr8Tech" or the "Company"), a logistics management innovation company, offering a diverse portfolio of technology-driven solutions, today announced the launch of its advanced AI Tendering Bot, an innovative solution designed to automate and streamline the load tendering process for shippers and freight brokers. This upgrade underscores Fr8Tech's strategic pivot to a Software-as-a-Service (SaaS) model, immediately enhancing service levels and automation for its enterprise clients. The launch also reinforces the Company's commitment to operational improvements and efficiencies through new technology to reduce operating costs for both Fr8Tech and its enterprise clients.
Transforming Load Tendering with Artificial Intelligence
Traditionally, load tendering has relied on integrated Transport Management Systems (TMS) solutions or outdated manual processes, such as assigning loads via text messages or emails. The AI Tendering Bot changes that by leveraging advanced artificial intelligence:
<ul>
<li>Identify Key Information: Seamlessly read and interpret emails, text messages, screenshots of Excel spreadsheets, and other documents containing load information</li>
<li>Real-Time Integration: Immediately post structured load data into the Fr8app marketplace, where carriers can instantly view and bid on available loads</li>
<li>Reduce Manual Intervention: Automate the transcription and organization of load requests, significantly reducing the time and labor required by employees</li>
</ul>

FRGT

Fr8Tech Launches AI Tendering Bot To Automate Load Tendering, Enhance SaaS Model And Reduce Costs

Apple&#xAE; today introduced the faster, more powerful iPad Air&#xAE; with the M3 chip and built for Apple Intelligence&#x2122;. iPad Air with M3 brings Apple's advanced graphics architecture to iPad Air for the first time — taking its incredible combination of power-efficient performance and portability to a new level. iPad Air with M3 is nearly 2x faster compared to iPad Air with M1,1 and up to 3.5x faster than iPad Air with A14 Bionic.2 Users will feel the speed of M3 in everything they do, from creating engaging content faster than ever to playing demanding, graphics-intensive games. Available in two sizes and four gorgeous finishes that users love, the 11-inch iPad Air is super portable while on the go, and the 13-inch model provides an even larger display for more room to be creative and productive. Designed for iPad Air, the new Magic Keyboard&#xAE; enhances its versatility and delivers more capabilities at a lower price. With iPadOS&#xAE; 18, support for Apple Intelligence, advanced cameras, fast wireless 5G connectivity, and compatibility with Apple Pencil Pro&#x2122; and Apple Pencil&#xAE; (USB-C), the new iPad Air offers an unrivaled experience.

Apple Introduces iPad Air With Powerful M3 Chip And New Magic Keyboard

Acquisition Accelerates Lightpath's Entrance into the Phoenix Market with 133 Route Miles of Operating Network and In Place Construction Capabilities
NEW YORK, March 4, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4374794-1&amp;h=554530659&amp;u=https%3A%2F%2Flightpathfiber.com%2F%3Futm_source%3DPR%26utm_campaign%3D20250304&amp;a=Lightpath">Lightpath</a>, an all fiber, infrastructure based connectivity provider revolutionizing how organizations connect to their digital destinations, announced the company has completed the acquisition of WANRack's network assets and customers in the Phoenix metropolitan market. This acquisition adds 133 route miles of fiber, including diverse paths between the Goodyear data center ecosystem and metro Phoenix carrier hotel facilities, accelerating Lightpath's service readiness and expansion in the region.

ATUS

LPTH

Lightpath Acquires WANRack's Phoenix Business; No Financial Terms Disclosed

Goldman Sachs analyst Kash Rangan maintains Definitive Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DH#NASDAQ">DH</a>) with a Neutral and lowers the price target from $4.5 to $3.

Goldman Sachs Maintains Neutral on Definitive Healthcare, Lowers Price Target to $3

On Tuesday, Accenture (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>)&nbsp;announced it has acquired&nbsp;Halfspace, a <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44102381/accenture-acquires-halfspace-to-bolster-ai-capabilities-in-the-nordic-region" rel="noreferrer noopener">Denmark-based AI company</a>&nbsp;that helps organizations leverage and scale AI to make better,&nbsp;more informed decisions faster. The financial terms of the deal remain undisclosed.
The acquisition enhances Accenture&#8217;s AI capabilities and talent in Nordic and European regions.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44083704/verizon-and-accenture-partner-to-expand-cybersecurity-services-and-strengthen-business-protections" rel="noreferrer noopener">Verizon and Accenture Partner to Expand Cybersecurity Services and Strengthen Business Protections</a>
With the addition of Halfspace, Accenture will extend the Center for Advanced AI into the Nordics, focused on helping clients capture and create value from AI.
Founded in 2015, Halfspace develops AI and generative AI solutions and products that drive value creation by streamlining complex business workflows and uses advanced analytics and data science to transform data into actionable insights.
Halfspace adds nearly 80 highly qualified AI practitioners to Accenture&#8217;s Nordic AI practice. The company also has strong ecosystem relationships with leading AI platform companies, including Databricks, Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), and Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>).
Accenture also snapped up Altus Consulting to further enhance its strategic advisory and delivery services for insurance, investments, and other financial services businesses <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44102865/accenture-acquires-altus-consulting-to-strengthen-capabilities-for-insurance-and-investments-clien" rel="noreferrer noopener">across the UK</a>. The financial terms of this deal remain undisclosed.
Founded in 2005, Altus Consulting has developed advisory services with deep knowledge of the operating models, data, and platforms that power financial services organizations.
Altus Consulting&#8217;s highly skilled team will join Accenture&#8217;s&nbsp;Insurance practice&nbsp;in the UK, bringing expertise in areas including distribution, risk and regulation, operating models, data, and technology.
Accenture&#8217;s total cash balance on November 30, 2024, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42572094/accenture-reports-first-quarter-fiscal-2025-results" rel="noreferrer noopener">was $8.3 billion</a>.
Accenture stock has been down over 10% in the last 12 months. At least <a target="_blank" href="https://www.benzinga.com/quote/ACN/analyst-ratings" rel="noreferrer noopener">two Wall Street firms</a>, Jefferies and Stifel, cut their price targets on the stock in 2025.
Accenture reported&nbsp;<a target="_blank" href="https://www.benzinga.com/24/12/42586612/accenture-delivers-q1-revenue-growth-bolstered-by-consulting-and-managed-services" rel="noreferrer noopener">first-quarter fiscal 2025</a> sales of $17.69 billion compared with the analyst consensus estimate of $17.12 billion, up 9%.&nbsp;
The adjusted EPS of $3.59 topped the&nbsp;analyst consensus estimate of $3.39. Accenture expects second-quarter revenues of $16.2 billion–$16.8 billion (versus&nbsp;consensus of $16.63 billion).
Price Action: ACN stock traded lower by 1.16% to $341.01 premarket at the last check on Tuesday.

Eurozone

MSFT

Accenture M&A: Acquires AI Firm Halfspace, Altus Consulting In UK To Expand Advanced AI Solutions in Europe

Contracts

ICLR

Mural Health Technologies Enters Partnership With ICON To Utilize Mural Link For Trial Payments, Travel Support, And Communication Tools

Riot Produces 470 Bitcoin in February 2025
CASTLE ROCK, Colo., March 4, 2025 /PRNewswire/ -- Riot Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>) ("Riot" or "the Company"), an industry leader in vertically integrated Bitcoin ("BTC") mining, announces unaudited production and operations updates for February 2025.&nbsp;&nbsp;
Bitcoin Production and Operations Updates for February 2025
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="2" rowspan="1">Comparison (%)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Metric</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">February 2025 1</td>
<td colspan="1" rowspan="1">January 2024 1</td>
<td colspan="1" rowspan="1">February 2024</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Month/Month</td>
<td colspan="1" rowspan="1">Year/Year</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Bitcoin Produced</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">470</td>
<td colspan="1" rowspan="1">527</td>
<td colspan="1" rowspan="1">418</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">-11&nbsp;%</td>
<td colspan="1" rowspan="1">12&nbsp;%</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Average Bitcoin Produced per Day</td>
<td colspan="1" rowspan="1">16.8</td>
<td colspan="1" rowspan="1">17.0</td>
<td colspan="1" rowspan="1">14.4</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">-1&nbsp;%</td>
<td colspan="1" rowspan="1">16&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Bitcoin Held 2</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">18,692</td>
<td colspan="1" rowspan="1">18,221</td>
<td colspan="1" rowspan="1">8,067</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">3&nbsp;%</td>
<td colspan="1" rowspan="1">132&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Bitcoin Sold</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">N/A</td>
<td colspan="1" rowspan="1">N/A</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Bitcoin Sales - Net Proceeds</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">N/A</td>
<td colspan="1" rowspan="1">N/A</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Average Net Price per Bitcoin Sold</td>
<td colspan="1" rowspan="1">N/A</td>
<td colspan="1" rowspan="1">N/A</td>
<td colspan="1" rowspan="1">N/A</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">N/A</td>
<td colspan="1" rowspan="1">N/A</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Deployed Hash Rate - Rockdale 2</td>
<td colspan="1" rowspan="1">15.0 EH/s</td>
<td colspan="1" rowspan="1">15.0 EH/s</td>
<td colspan="1" rowspan="1">12.4 EH/s</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">0&nbsp;%</td>
<td colspan="1" rowspan="1">21&nbsp;%</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Deployed Hash Rate - Corsicana 2</td>
<td colspan="1" rowspan="1">15.7 EH/s</td>
<td colspan="1" rowspan="1">15.7 EH/s</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">0&nbsp;%</td>
<td colspan="1" rowspan="1">N/A</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Deployed Hash Rate - Kentucky 2</td>
<td colspan="1" rowspan="1">2.9 EH/s</td>
<td colspan="1" rowspan="1">2.8 EH/s</td>
<td colspan="1" rowspan="1">N/A</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">3&nbsp;%</td>
<td colspan="1" rowspan="1">N/A</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Deployed Hash Rate - Total 2</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">33.6 EH/s</td>
<td colspan="1" rowspan="1">33.5 EH/s</td>
<td colspan="1" rowspan="1">12.4 EH/s</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">0&nbsp;%</td>
<td colspan="1" rowspan="1">171&nbsp;%</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Avg. Operating Hash Rate - Rockdale 3</td>
<td colspan="1" rowspan="1">12.9 EH/s</td>
<td colspan="1" rowspan="1">12.7 EH/s</td>
<td colspan="1" rowspan="1">8.5 EH/s</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">2&nbsp;%</td>
<td colspan="1" rowspan="1">52&nbsp;%</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Avg. Operating Hash Rate - Corsicana 3</td>
<td colspan="1" rowspan="1">13.9 EH/s</td>
<td colspan="1" rowspan="1">14.2 EH/s</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">-2&nbsp;%</td>
<td colspan="1" rowspan="1">N/A</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Avg. Operating Hash Rate - Kentucky 3</td>
<td colspan="1" rowspan="1">2.6 EH/s</td>
<td colspan="1" rowspan="1">2.4 EH/s</td>
<td colspan="1" rowspan="1">N/A</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">7&nbsp;%</td>
<td colspan="1" rowspan="1">N/A</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Avg. Operating Hash Rate - Total 3</td>
<td colspan="1" rowspan="1">29.4 EH/s</td>
<td colspan="1" rowspan="1">29.3 EH/s</td>
<td colspan="1" rowspan="1">8.5 EH/s</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">0&nbsp;%</td>
<td colspan="1" rowspan="1">246&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Power Credits 4</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$2.1 million</td>
<td colspan="1" rowspan="1">$3.2 million</td>
<td colspan="1" rowspan="1">$0.7 million</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">-36&nbsp;%</td>
<td colspan="1" rowspan="1">180&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Demand Response Credits 5</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$0.7 million</td>
<td colspan="1" rowspan="1">$1.0 million</td>
<td colspan="1" rowspan="1">$0.2 million</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">-25&nbsp;%</td>
<td colspan="1" rowspan="1">249&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total Power Credits</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$2.8 million</td>
<td colspan="1" rowspan="1">$4.2 million</td>
<td colspan="1" rowspan="1">$1.0 million</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">-33&nbsp;%</td>
<td colspan="1" rowspan="1">196&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">All-in Power Cost - Rockdale 6</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">3.5c/kWh</td>
<td colspan="1" rowspan="1">3.4c/kWh</td>
<td colspan="1" rowspan="1">4.0c/kWh</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">4&nbsp;%</td>
<td colspan="1" rowspan="1">-11&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">All-in Power Cost - Corsicana 6</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">3.7c/kWh</td>
<td colspan="1" rowspan="1">3.4c/kWh</td>
<td colspan="1" rowspan="1">N/A</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">8&nbsp;%</td>
<td colspan="1" rowspan="1">N/A</td>
</tr>
<tr>
<td colspan="1" rowspan="1">All-in Power Cost - Kentucky 6</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">4.0c/kWh</td>
<td colspan="1" rowspan="1">3.9c/kWh</td>
<td colspan="1" rowspan="1">N/A</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">4&nbsp;%</td>
<td colspan="1" rowspan="1">N/A</td>
</tr>
<tr>
<td colspan="1" rowspan="1">All-in Power Cost - Total 6</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">3.6c/kWh</td>
<td colspan="1" rowspan="1">3.4c/kWh</td>
<td colspan="1" rowspan="1">4.0c/kWh</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">7&nbsp;%</td>
<td colspan="1" rowspan="1">-8&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Fleet Efficiency 2</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">21.0 J/TH</td>
<td colspan="1" rowspan="1">21.1 J/TH</td>
<td colspan="1" rowspan="1">27.0 J/TH</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">-1&nbsp;%</td>
<td colspan="1" rowspan="1">-22&nbsp;%</td>
</tr>
</tbody>
</table>
</figure>
<ol>
<li>Unaudited, estimated.</li>
<li>As of month-end.</li>
<li>Average over the month.</li>
<li>Estimated power curtailment credits.</li>
<li>Estimated credits received from participation in&nbsp;ERCOT and MISO demand response programs.</li>
<li>Estimated. Inclusive of all transmission and distribution charges, fees, adders, and taxes. Net of Total Power Credits.</li>
</ol>

RIOT

Riot Announces February 2025 Production And Operations Updates; 470 Bitcoin Produced; 18,692 Bitcoin Held

FedRAMP Moderate authorization for SailPoint's Non-Employee Risk Management product further demonstrates commitment to maintaining compliance and operational efficiency

SAIL

SailPoint's Non-Employee Risk Management Achieves FedRAMP Authorization

ALMS

SLRN

ACELYRIN Board Determined The Unsolicited Indication Of Interest From Concentra Biosciences Was 'Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger'

Goldman Sachs analyst Mike Harris maintains Cleveland-Cliffs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) with a Buy and lowers the price target from $17 to $15.

Goldman Sachs Maintains Buy on Cleveland-Cliffs, Lowers Price Target to $15

The Campbell&#8217;s Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NASDAQ">CPB</a>) will release its second-quarter financial results, before the <a href="https://www.benzinga.com/quote/CPB/earnings">opening bell, on Wednesday.</a>
Analysts expect the company to report quarterly earnings at 72 cents per share, down from 80 cents per share in the year-ago period. Campbell&#8217;s projects quarterly revenue of $2.74 billion, compared to $2.46 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Jan. 22, The Campbell&#8217;s Company named Risa Cretella as executive vice President and president, Meals &amp; Beverages.
With the recent buzz around Campbell&#8217;s, some investors may be eyeing potential gains from the company's dividends too. As of now, Campbell&#8217;s offers an annual dividend yield of 3.78%, which is a quarterly dividend amount of 39 cents per share ($1.56 a year). &nbsp;
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $158,801 or around 3,846 shares. For a more modest $100 per month or $1,200 per year, you would need $31,752 or around 769 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($1.56 in this case). So, $6,000 / $1.56 = 3,846 ($500 per month), and $1,200 / $1.56 = 769 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
CPB Price Action: Shares of Campbell&#8217;s gained 3.1% to close at $41.29 on Monday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/03/44083539/wall-streets-most-accurate-analysts-give-their-take-on-3-defensive-stocks-delivering-high-dividend-yields-3">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Defensive Stocks Delivering High-Dividend Yields</a></li>
</ul>
Photo: JHVEPhoto via Shutterstock

Earnings

Long Ideas

Markets

Trading Ideas

How To Earn $500 A Month From Campbell's Stock Ahead Of Q2 Earnings

Biotech

General

CING

Cingulate Reports Reports Safety Results From Final Phase 3 Trials CTx-1301 And Submits Results Ahead Of In-person FDA Meeting Set For Apr. 2; Says No Subjects Have Experienced A Serious Treatment Emergent Adverse Event (TEAE), A Serious TEAE Or A TEAE Leading To Death

Dear Shareholders,
I am happy to take this opportunity to provide our shareholders with an overview of our key accomplishments and outline our future direction.&nbsp;
Oramed-HTIT Joint Venture: OraTech - A Transformational Partnership
We are excited about our joint venture, OraTech Pharmaceuticals, Inc. ("OraTech"), which we believe represents a significant step forward in advancing our proprietary oral drug delivery technology. This company will serve as the foundation for developing, marketing, and commercializing innovative treatments leveraging Oramed's oral insulin and POD&#x2122; platform.
The collaboration combines Oramed's innovative drug delivery technology with Hefei Tianhui Biotech Co., Ltd's ("HTIT") state-of-the-art manufacturing capabilities, creating a powerful synergy that we believe positions OraTech as a true game-changer in the pharmaceutical industry. This integration of cutting-edge technology and advanced manufacturing expertise will enable us to ensure consistent, high-quality production at scale, setting new standards for oral protein delivery.
OraTech is backed by a substantial capital and operational commitment. These resources are earmarked to support the initiation of a Phase 3 clinical trial in the U.S., a key milestone in bringing oral insulin to market. By leveraging insights from prior clinical studies, we have strategically designed this refined Phase 3 trial to focus on key patient subpopulations that we believe have the highest potential to demonstrate efficacy.
In parallel, HTIT has already submitted a Marketing Authorization Application to China's regulators for the oral insulin capsule in China. Commercialization preparations are underway, and OraTech is expected to receive royalties from sales in China.
The establishment of OraTech represents a unique opportunity to build a company focused on advancing next-generation therapies, unlocking new market potential.
Stock Dividend and Strategic Opportunities
OraTech has initiated work on the Securities and Exchange Commission registration process with the goal of achieving Nasdaq trading status later this year. As part of this strategic initiative, Oramed plans to distribute OraTech stock to its shareholders via a dividend, granting them the majority of Oramed's ownership in OraTech. This distribution is expected to coincide with OraTech's public trading debut on Nasdaq.
Cash Dividend
Oramed is evaluating an opportunity to issue cash dividends of approximately $0.25 per share intended to help offset any potential tax liabilities associated with the OraTech stock distribution. Beyond mitigating potential tax concerns, this initiative underscores our commitment to maximizing shareholder value.
Strategic Scilex Financing : Delivering Tangible Value
Our investment in Scilex Holding Company ("Scilex") underscores our commitment to generating meaningful value through well-structured financial transactions. To date, we have received $70 million from our $99.5 million secured loan agreement, with additional payments of approximately $53 million expected over the&nbsp; next two years.
Beyond these direct financial returns, the transaction has provided us with 12.25 million shares of Scilex common stock, which will increase to 18.75 million shares this month as a result of warrant vesting. Additionally, we structured this deal to include meaningful upside through ongoing royalty streams from the following Scilex products:
<ul>
<li>ZTlido – A 4% royalty on sales worldwide for the next decade and a 25% profit share on the majority of sales outside the U.S., leveraging its U.S. Food and Drug Administration approval as a lidocaine topical system targeting the global pain patch market valued at $4.8 billion in 2021, and is projected to reach $7.3 billion by 2031. Oramed will receive $400,000 in royalties for Q4 2024 and expects this amount to increase on a quarterly basis. More details at <a href="https://ztlido.com/">www.ztlido.com</a>.</li>
<li>ELYXYB – The first ready-to-use oral solution for acute migraines, addressing a condition that affects approximately 39 million Americans. We hold a 2% royalty on worldwide sales. More details at <a href="https://www.elyxyb.com/">www.elyxyb.com</a>.</li>
<li>GLOPERBA – An innovative oral liquid formulation for gout treatment, tapping into a market with strong growth potential. We hold a 2% royalty on worldwide sales and a 25% profit share on the majority of sales outside the U.S. More details at <a href="https://www.gloperba.com/">www.gloperba.com</a>.</li>
</ul>
Strong Balance Sheet: Positioned for Growth and Value Creation
Oramed maintains a robust financial position, strengthened by our strategic Scilex transaction and the OraTech joint venture. Our disciplined approach to cash management includes CDs, bonds, real estate and equities. We believe that our disciplined capital allocation strategy enables us to maintain sufficient liquidity for both our core operations and strategic initiatives, positioning Oramed for sustainable long-term growth.
Looking Ahead: A Commitment to Strategic Growth
Looking forward, we are actively pursuing acquisitions and partnerships that leverage our expertise in technology development and strategic dealmaking. We have identified several promising opportunities across multiple innovation ecosystems and expect to announce additional strategic initiatives in the coming quarters.
Sincerely, Nadav Kidron&nbsp; Chief Executive Officer

ORMP

Oramed Pharmaceuticals Issues Letter To Shareholders From President And CEO Nadav Kidron

Macro Economic Events

Econ #s

Economics

U.S. Commerce Secretary Lutnick Says On April 2 We Will See A Reordering And A Renegotiation Of Trade With U.S. Trading Partners Under Reciprocal Tariff Action

Comments

Avantis Emerging Markets Equity ETF

Noticias

Últimas noticias sobre Avantis Emerging Markets Equity ETF (ARCA:AVEM)

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL